Concurrent oral and genital infection with HPV DNA types 6 and 11 in a heterosexual male

Objective Detection of HPV DNA in oral and genital lesions of a heterosexual male. 4 months after oral and vaginal intercourse with a woman with vulvar warts. Passible modes of acquisition of oral HPV infection in the male sexual partner are discussed. Setting Genitourinary Medicine clinic. Methods Polymerase chain reaction amplification of genomic DNA from oral and genital lesions. HPV DNA typing by dot blot hybridization. Results HPV DNA types 6 and 11 were identified in a polypoid tongue lesion and in a penile wart from the male sexual partner. Conclusions The acquisition of oral HPV infection in the male sexual partner may have resulted from genital-oral HPV transfer, either by direct contact with vulvar warts or by digital self-inoculation.     

介绍一种不加盖玻片的核酸原位杂交改良法

核酸原位杂交程序中探针和靶基因的加热变性和杂交为整个程序中最重要的环节,目前国内外最常用的方法是在切片上滴加DNA探针溶液后用盖玻片复盖组织,并加胶泥或其他封固剂封闭玻片四周,变性杂交后需拆除盖玻片,这一操作过程易损坏组织切片或出现干片、脱片。作者针对上述情况,对传统的核酸原位杂交方法中的部分程序加以改良,采用不加盖玻片直接在蒸汽中变性方法,经多次实验证明此方法稳定、可靠、简便,结果满意。     

哈乐在良性前列腺增生伴急性尿潴留中的应用

目的 :探讨α1A肾上腺素能受体阻滞剂哈乐 (tamsulosin)对良性前列腺增生 (BPH)伴急性尿潴留病人的治疗作用。方法 :对 72例BPH伴急性尿潴留病人采用随机、对照研究 ,分为治疗组和对照组。病人均行保留导尿 ,口服抗生素治疗。治疗组加用哈乐 0 .4mg ,1次 /d ,连续服用 3次。 72h后拔除导尿管。　结果 :拔除导尿管后 4 4 % (32 / 72 )的病人能自行排尿。有效率治疗组为 6 1% (2 2 / 36 ) ,对照组为 2 8% (10 / 36 ) ,两组比较差异有显著性 (P <0 .0 1)。　结论 :对BPH伴急性尿潴留应用哈乐治疗 ,可提高早期拔除导尿管后病人自行排尿的成功率 ,且疗效与前列腺体积大小无关。     

人乳头瘤病毒多肽与人免疫球蛋白G融合表达

目的 将人乳头瘤病毒16型(Human papillomavirus type 16，HPV-16)的晚期表达蛋白E7上的抗原24肽(从第38位氨基酸到第61位氨基6病毒感染防治酸)与人免疫球蛋白G的重链恒定区融合表达，并以此融合蛋白作为抗原，可能为HPV-1提供免疫治疗方法。方法 利用PCR方法分别扩增HPV-16 E7(38-61)24肽的DNA片段和人免疫球蛋白G的重链恒定区DNA片段，并构建到pEV21a表达载体上，转化入E．coli中表达，利用SDS-聚丙烯酰胺凝胶电泳(SDS-PAGE)和蛋白质免疫印迹(Western-blotting)的方法对表达结果进行鉴定。结果 构建的表达载体HPV16E7e／hIgGHCCR-pET21a经酶切鉴定和测序显示序列正确；通过SDS-PAGE和Western-blotting的鉴定，重组融合蛋白Mr约40000，表达量可占菌体蛋白的20％左右。结论 成功构建HPV16-E7的抗原多肽片段和人免疫球蛋白G的重链恒定区的融合蛋白，并可在E．coli中高效表达。     

76例宫颈癌组织中人类乳头瘤病毒的检测

本文应用ＨＰＶ－ＰＣＲ技术和ＤＮＡ杂交技术对７６例宫颈鳞癌标本进行了ＨＰＶ－ＤＮＡ的研究，发现ＨＰＶ－ＤＮＡ存在率为９０．７９％（６９／７６），主要类型为ＨＰＶ１６和１８。多酶切ＳｏｕｔｈｅｒｎＢｌｏｔ杂交证实在宫颈癌中９２．５６％的ＨＰＶ－ＤＮＡ发生变异，说明ＨＰＶ－ＤＮＡ的基因变异与其致癌作用密切相关。ＰＣＲ结果证实ＨＰＶ－Ｅ６片段在宫颈癌组织中常可出现，推测可能是致癌的关键片段之一。因此，检测宫颈癌组织中ＨＰＶ－ＤＮＡ的完整性、关键基因片段的存在与否，可能对于病变恶变的预测有一定的意义     

上海地区女性生殖道人乳头瘤病毒感染的检测

应用地高辛甙元标记人乳头瘤病毒(HPV)-6,11,16和18探针,通过核酸杂交法检测上海地区女性患者HPV的感染。计活检组织标本128例,阴道脱落细胞130例,同时取样34例。斑点杂交结果表明活检组织中四种类型HPV的总阳性率:宫颈癌44％,宫颈间变66.7％,有间变史28.6％,外阴尖锐湿疣63％和慢性宫颈炎5.6％。阴道脱落细胞的各阳性率与之相近,同时取样的检测符合率为91.2％。Southern转移杂交结果提示:宫颈癌以HPV-16型为主,尖锐湿疣中的HPV为6和11型     

Nucleic acid spot hybridization with nonradioactive labeled probes in screening for human papillomavirus DNA sequences

We examined 161 human tissue samples using the spot hybridization technique with nonradioactive labeled DNA probes of human papillomavirus (HPV). Whole cells were spotted on nitrocellulose filters; DNA of the cells was denatured and fixed to the filter. Then the DNA spots were hybridized to nonradioactive labeled DNA and monitored by a sandwich immunoenzymatic reaction. This technique is simple, sensitive, specific, requires no special equipment, and can be used in clinical settings. HPV DNA was found in 92% of samples in which, on the basis of histologic and colposcopic criteria, its presence was suspected, as well as in 31 samples where it was not suspected.     

Detection of human papillomavirus in organs of upper genital tract in women with cervical cancer

In this study, we evaluated the presence of human papillomavirus (HPV) DNA in organs of the female upper genital tract, using nine hysterectomy and salpingo-oophorectomy specimens affected by HPV-positive invasive cervical carcinomas, to establish if cervical HPV infection can spread to upper tracts of the female genital system. HPV DNA was evaluated by polymerase chain reaction (PCR) in all cervical carcinomas as well as in all tracts of the genital system. Then, these data were compared with the results obtained from PCR study of five other hysterectomy and salpingo-oophorectomy specimens (control cases). The criteria used for selection of the control cases were informed consent of the patients for research at the time of surgery, absence of neoplasms, absence of any anatomic lesion caused by HPV in cervix, and external genitalia. All selected cases were squamous cervical carcinomas. PCR analysis revealed HPV DNA in all cases of cervical carcinoma. The HPV DNA was detected as weak positivity on PCR analysis in other organs of the genital system. However, the distribution of HPV DNA varied in the various cases and in the different tracts of the same hysterectomy and salpingo-oophorectomy specimen. We believe that the HPV DNA, detected as a weakly positive signal, in the upper genital tract of patients who have a cervical squamous carcinoma could be a reflection of a latent HPV infection, as well as a sign of the existence of micrometastases containing HPV DNA, which cannot be detected by conventional histologic techniques.     

HPV检测和液基细胞学检查在宫颈病变筛查中的应用

目的 通过与病理组织学检查结果比较,评价高危型人乳头瘤病毒(HR-HPV)检测和液基细胞学检查在宫颈病变筛查中的应用价值.方法 对2004年12月～2006年12月在解放军总医院行HR-HPV和液基细胞学检查及电子阴道镜下宫颈活组织病理检查的690例患者的资料进行回顾性分析.结果 690例患者中液基细胞学与病理组织学检查的符合率为:低度鳞状上皮内病变(LSIL)22.34%(42/188),高度鳞状上皮内病变(HSIL)58.33%(56/96),宫颈癌100%(16/16).细胞学结果 示良性细胞改变75例;不典型鳞状细胞(ASC)、LSIL、HSIL和宫颈癌者分别为315、188、96、16例,其HR-HPV阳性率分别为53.96%(170/315)、77.12%(134/188)、80.21%(77/96)和100%(16/16).经阴道镜下多点活检病理组织学诊断为炎症、上皮内瘤变Ⅰ级和(或)湿疣(CIN Ⅰ/HPV)、CIN Ⅱ/CIN Ⅲ、宫颈浸润癌者分别为425、81、157和27例,其HR-HPV阳性率分别为43.29%(184/425)、74.93%(60/81)、91.72%(144/157)和92.5%(25/27).此外,413例HR-HPV阳性者中,病理学≥CIN Ⅰ/HPV者占55.45%(229/413);277例HR-HPV阴性者中,病理学为炎症者占87.01%(241/277),≥CIN Ⅰ/HPV者占12.99%(36/277),而36例≥CIN Ⅰ/HPV者中CIN Ⅱ/CIN Ⅲ和宫颈浸润癌仅占5.42%(15/277).315例ASC中,HR-HPV阳性者170例,病理学≥CIN Ⅰ/HPV占41.76%(71/170),其中CIN Ⅱ/CIN Ⅲ和宫颈浸润癌占69.01%(49/71);HR-HPV阴性145例,病理学≥CIN Ⅱ/CIN Ⅲ者仅占4.83%(7/145),炎症占90.34%(131/145).结论 HR-HPV和液基细胞学检查是筛查宫颈病变的有效方法 ,二者结合有利于宫颈病变的分流管理,提高宫颈癌及癌前病变的检出率.